Literature DB >> 1303193

A frameshift mutation in the HuP2 paired domain of the probable human homolog of murine Pax-3 is responsible for Waardenburg syndrome type 1 in an Indonesian family.

R Morell1, T B Friedman, S Moeljopawiro, J H Asher.   

Abstract

Waardenburg syndrome type 1 (WS1) is an autosomal dominant disorder characterized by deafness, dystopia canthorum, heterochromia iridis, white forelock, and premature greying. A similar phenotype is caused in the mouse by mutations in the Pax-3 gene. This observation, together with comparisons of conserved syntenies in the murine and human genetic maps, suggested that at least some WS1 mutations should occur in HuP2, the probable human homolog of Pax-3. Two mutations in the HuP2 sequence of individuals with WS1 have been reported recently. Both of them occur in the highly conserved paired box region of the gene, which encodes a DNA binding domain. The functional consequences of these mutations are at present speculative. We report here a 14 bp deletion in the paired domain encoded by exon 2 of HuP2 in an Indonesian family segregating for WS1. This frameshift mutation results in a premature termination codon in exon 3. The HuP2 product is a truncated protein lacking most of the paired domain and all of the predicted homeo domain. We propose that the WS1 phenotype in this family is due to loss of function of HuP2 and discuss two mechanisms for the dominant effect of this mutation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1303193     DOI: 10.1093/hmg/1.4.243

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  23 in total

Review 1.  Waardenburg syndrome.

Authors:  A P Read; V E Newton
Journal:  J Med Genet       Date:  1997-08       Impact factor: 6.318

Review 2.  Current perspectives on the genetic causes of neural tube defects.

Authors:  Patrizia De Marco; Elisa Merello; Samantha Mascelli; Valeria Capra
Journal:  Neurogenetics       Date:  2006-08-29       Impact factor: 2.660

Review 3.  The incidence of deafness is non-randomly distributed among families segregating for Waardenburg syndrome type 1 (WS1).

Authors:  R Morell; T B Friedman; J H Asher; L G Robbins
Journal:  J Med Genet       Date:  1997-06       Impact factor: 6.318

Review 4.  Transcription factors in inner ear development.

Authors:  D P Corey; X O Breakefield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

5.  Identification of rare paired box 3 variant in strabismus by whole exome sequencing.

Authors:  Hui-Min Gong; Jing Wang; Jing Xu; Zhan-Yu Zhou; Jing-Wen Li; Shu-Fang Chen
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

6.  Isolation of two isoforms of the PAX3 gene transcripts and their tissue-specific alternative expression in human adult tissues.

Authors:  K Tsukamoto; Y Nakamura; N Niikawa
Journal:  Hum Genet       Date:  1994-03       Impact factor: 4.132

7.  Association of transforming growth-factor alpha gene polymorphisms with nonsyndromic cleft palate only (CPO).

Authors:  R Shiang; A C Lidral; H H Ardinger; K H Buetow; P A Romitti; R G Munger; J C Murray
Journal:  Am J Hum Genet       Date:  1993-10       Impact factor: 11.025

Review 8.  Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease.

Authors:  Jennifer D Kubic; Kacey P Young; Rebecca S Plummer; Anton E Ludvik; Deborah Lang
Journal:  Pigment Cell Melanoma Res       Date:  2008-12       Impact factor: 4.693

9.  Paired-type homeodomain transcription factors are imported into the nucleus by karyopherin 13.

Authors:  Jonathan E Ploski; Monee K Shamsher; Aurelian Radu
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

10.  A frameshift mutation in the gene for PAX3 in a girl with spina bifida and mild signs of Waardenburg syndrome.

Authors:  F A Hol; B C Hamel; M P Geurds; R A Mullaart; F G Barr; R A Macina; E C Mariman
Journal:  J Med Genet       Date:  1995-01       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.